Hudson Bay Capital Management LP Has $3.57 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• Hudson Bay Capital boosted its stake in Pfizer by 1,784.7% in Q3, owning 140,165 shares worth about $3.57 million at quarter-end.
• Pfizer beat quarterly expectations (EPS $0.66 vs $0.57; revenue $17.56B vs $16.93B) and reported positive oncology trial results (TALZENNA+XTANDI Phase 3 and atirmociclib Phase II), supporting pipeline momentum beyond vaccines.
• Pfizer recommended shareholders reject a conditional mini‑tender offer from Tutanota LLC to buy up to 1M shares at $32, while analysts’ consensus remains a "Hold" with an average target of $28.14.

Hudson Bay Capital Management LP boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 1,784.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 140,165 shares of the biopharmaceutical company's stock after purchasing an additional 132,728 shares during the period. Hudson Bay Capital Management LP's holdings in Pfizer were worth $3,571,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Peak Asset Management LLC grew its position in Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company's stock worth $697,000 after acquiring an additional 402 shares during the last quarter. Quest Investment Management LLC raised its position in Pfizer by 1.3% in the third quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company's stock valued at $809,000 after purchasing an additional 405 shares during the last quarter. Community Bank & Trust Waco Texas raised its position in Pfizer by 0.6% in the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company's stock valued at $1,703,000 after purchasing an additional 412 shares during the last quarter. CVA Family Office LLC boosted its stake in shares of Pfizer by 3.3% during the third quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company's stock valued at $329,000 after purchasing an additional 413 shares in the last quarter. Finally, Boltwood Capital Management grew its holdings in shares of Pfizer by 0.7% during the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company's stock worth $1,485,000 after purchasing an additional 420 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE stock opened at $26.98 on Friday. The firm has a 50 day moving average of $26.68 and a 200-day moving average of $25.61. The company has a market cap of $153.41 billion, a price-to-earnings ratio of 19.84 and a beta of 0.47. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer's quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.63 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Topline Phase 3 win for TALZENNA (talazoparib) + XTANDI: the TALAPRO-3 study met its primary endpoint, showing a significant delay in radiographic progression-free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer — a meaningful commercial and clinical win for Pfizer's oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Additional oncology progress: a Phase II study of atirmociclib in second‑line metastatic breast cancer hit its primary endpoint, supporting pipeline diversification beyond vaccines and COVID-era revenues. PFE's Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst interest/upgrade flow: recent analyst upgrades and a bullish HSBC forecast have lent buy‑side support and renewed attention to Pfizer’s valuation and upside potential. Pfizer NYSE: PFE Stock Price Up 3.2% Following Analyst Upgrade
• Neutral Sentiment: Pfizer-linked investment activity: Earendil Labs closed a $787M financing that included participation from a biotech development fund associated with Pfizer — a sign of strategic R&D/venture exposure but not an immediate earnings driver. Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
• Neutral Sentiment: Market commentary and valuation focus: several recent pieces reassess Pfizer’s valuation and compare it to peers (e.g., Moderna), keeping the stock in investors’ screens but creating mixed sentiment around near‑term upside. Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels
• Negative Sentiment: Unsolicited mini‑tender offer: Tutanota LLC filed a conditional mini‑tender to buy up to 1M Pfizer shares at $32 — Pfizer has advised shareholders to reject it. The offer is unlikely to be material but can create short‑term trading noise. Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PFE. Wolfe Research set a $24.00 price objective on Pfizer and gave the company an "underperform" rating in a research note on Wednesday, December 17th. Citigroup started coverage on shares of Pfizer in a report on Tuesday, December 2nd. They set a "neutral" rating and a $26.00 target price on the stock. Daiwa Securities Group cut shares of Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price target for the company. in a research report on Thursday, February 12th. Zacks Research raised shares of Pfizer from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 24th. Finally, Royal Bank Of Canada assumed coverage on shares of Pfizer in a research note on Tuesday, February 24th. They issued an "underperform" rating and a $25.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.14.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.